These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

479 related articles for article (PubMed ID: 25200487)

  • 61. New European commission regulation on variations to the terms of marketing authorization for medicinal products and its impact on Croatian legislation.
    Martinac AI; Tomić S; Simicić M
    Arh Hig Rada Toksikol; 2010 Sep; 61(3):311-22. PubMed ID: 20860972
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [Comments on the monographies of drugs of botanical origin of the European Pharmacopoeia (Volume I and II) (author's transl)].
    Lemli J
    J Pharm Belg; 1975; 30(5-6):443-54. PubMed ID: 2657
    [No Abstract]   [Full Text] [Related]  

  • 63. Use of reference substances in pharmacopoeia specifications.
    Johnson CA
    Ann Ist Super Sanita; 1975; 11(3-4):314-21. PubMed ID: 1234733
    [TBL] [Abstract][Full Text] [Related]  

  • 64. The use of community herbal monographs to facilitate registrations and authorisations of herbal medicinal products in the European Union 2004-2012.
    Peschel W
    J Ethnopharmacol; 2014 Dec; 158 Pt B():471-86. PubMed ID: 25043780
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [The use of nanotechnology in medicinal products in the light of European Union law].
    Jurewicz M
    Pol Merkur Lekarski; 2014 Dec; 37(222):369-72. PubMed ID: 25715580
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Reduction of animal usage: British Pharmacopoeia Commission policy.
    Rabouhans ML
    Dev Biol Stand; 1986; 64():11-6. PubMed ID: 3792640
    [TBL] [Abstract][Full Text] [Related]  

  • 67. European commission consultation on pharmacovigilance.
    Waller P; Beard K; Egberts T; Evans S; Hallas J; Hasford J; Laporte JR; Moore N; Shakir S; Sturkenboom M
    Pharmacoepidemiol Drug Saf; 2008 Feb; 17(2):108-9. PubMed ID: 18058839
    [No Abstract]   [Full Text] [Related]  

  • 68. International specification setting--EP perspectives. European Pharmacopoeia.
    Calam DH
    Dev Biol (Basel); 2002; 107():129-34. PubMed ID: 12079187
    [TBL] [Abstract][Full Text] [Related]  

  • 69. International Conference on Harmonisation; guidance on Q4B Evaluation and Recommendation of Pharmacopoeial Texts for Use in the International Conference on Harmonisation Regions; Annex 4A on Microbiological Examination of Nonsterile Products: Microbial Enumeration Tests General Chapter; availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2009 Apr; 74(66):15991-2. PubMed ID: 19507322
    [TBL] [Abstract][Full Text] [Related]  

  • 70. International Conference on Harmonisation; guidance on Q4B Evaluation and Recommendation of Pharmacopoeial Texts for Use in the International Conference on Harmonisation Regions; Annex 4B on Microbiological Examination of nonsterile products: Tests for Specified Microorganisms General Chapter; availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2009 Apr; 74(66):15989-90. PubMed ID: 19507320
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Modern European monographs for quality control of Chinese herbs.
    Bauer R; Franz G
    Planta Med; 2010 Dec; 76(17):2004-11. PubMed ID: 21077026
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Quality control of aromatic drugs reported in European Pharmacopoeia 3rd edition.
    Miraldi E; Giachetti D; Ferri S
    Farmaco; 2001; 56(5-7):365-71. PubMed ID: 11482760
    [TBL] [Abstract][Full Text] [Related]  

  • 73. The official compendia.
    Macek TJ
    Pharmacology; 1972; 8(1):204-6. PubMed ID: 4644650
    [No Abstract]   [Full Text] [Related]  

  • 74. Comparative Study of Pharmacopoeias in Japan, Europe, and the United States: Toward the Further Convergence of International Pharmacopoeial Standards.
    Kameyama Y; Matsuhama M; Mizumaru C; Saito R; Ando T; Miyazaki S
    Chem Pharm Bull (Tokyo); 2019; 67(12):1301-1313. PubMed ID: 31787657
    [TBL] [Abstract][Full Text] [Related]  

  • 75. [Standardization as a basis planning and administration in drug industry and pharmacy (II)].
    Wagler M
    Pharm Prax; 1970; 7():151-3. PubMed ID: 5469874
    [No Abstract]   [Full Text] [Related]  

  • 76. Quality Requirements for Medicinal Cannabis and Respective Products in the European Union - Status Quo.
    Veit M
    Planta Med; 2023 Jul; 89(8):808-823. PubMed ID: 35338476
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Regulatory aspects of stability testing in Europe.
    Matthews BR
    Drug Dev Ind Pharm; 1999 Jul; 25(7):831-56. PubMed ID: 10459489
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The evolving process of European combination product review, Part II.
    Donawa ME
    Med Device Technol; 2008; 19(7):26, 28-31. PubMed ID: 19133625
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Recommendations to eliminate subjective olfactory methods from compendial identification tests.
    Schwartzman G
    J Pharm Sci; 1978 Apr; 67(4):539-45. PubMed ID: 641764
    [TBL] [Abstract][Full Text] [Related]  

  • 80. [German pharmacopoeia, 7th edition. 5. Supply].
    Pharmazie; 1968 Oct; 23(10):534-40. PubMed ID: 5718868
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.